HK1117427A1 - Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer - Google Patents

Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer

Info

Publication number
HK1117427A1
HK1117427A1 HK08112329.9A HK08112329A HK1117427A1 HK 1117427 A1 HK1117427 A1 HK 1117427A1 HK 08112329 A HK08112329 A HK 08112329A HK 1117427 A1 HK1117427 A1 HK 1117427A1
Authority
HK
Hong Kong
Prior art keywords
parapoxviruses
biochemotherapy
cancer
treatment
combination
Prior art date
Application number
HK08112329.9A
Other languages
English (en)
Inventor
Olaf Weber
Original Assignee
Aicuris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37654955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1117427(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh filed Critical Aicuris Gmbh
Publication of HK1117427A1 publication Critical patent/HK1117427A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK08112329.9A 2005-11-24 2008-11-10 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer HK1117427A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05025600 2005-11-24
PCT/EP2006/009855 WO2007059821A1 (en) 2005-11-24 2006-10-12 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1117427A1 true HK1117427A1 (en) 2009-01-16

Family

ID=37654955

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08112329.9A HK1117427A1 (en) 2005-11-24 2008-11-10 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer

Country Status (15)

Country Link
US (1) US7897159B2 (es)
EP (1) EP1951274B1 (es)
JP (1) JP5164849B2 (es)
CN (1) CN101312737B (es)
AR (1) AR057922A1 (es)
AT (1) ATE450266T1 (es)
CA (1) CA2630833C (es)
DE (1) DE602006010902D1 (es)
DK (1) DK1951274T3 (es)
ES (1) ES2335308T3 (es)
HK (1) HK1117427A1 (es)
PL (1) PL1951274T3 (es)
PT (1) PT1951274E (es)
TW (1) TWI415617B (es)
WO (1) WO2007059821A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1848414T3 (pl) 2005-02-03 2011-10-31 Wyeth Llc Sposób leczenia nowotworu opornego na gefitinib
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
CN102202667A (zh) 2008-08-04 2011-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
MX356593B (es) 2009-04-06 2018-06-05 Wyeth Llc Régimen de tratamiento que utiliza neratinib para cáncer de mama.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3816139A1 (de) 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
LU90997B1 (en) * 2000-07-11 2003-01-08 Bayer Ag Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals ans anticancer pharmaceuticals
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
NZ512341A (en) * 2001-06-13 2004-02-27 Bayer Ag Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
EP2044948B1 (en) * 2002-08-12 2013-10-30 Jennerex Biotherapeutics ULC Vaccinia viruses for use in treating cancer

Also Published As

Publication number Publication date
CN101312737A (zh) 2008-11-26
EP1951274B1 (en) 2009-12-02
DK1951274T3 (da) 2010-02-01
PL1951274T3 (pl) 2010-05-31
ES2335308T3 (es) 2010-03-24
DE602006010902D1 (de) 2010-01-14
JP2009517347A (ja) 2009-04-30
TWI415617B (zh) 2013-11-21
WO2007059821A1 (en) 2007-05-31
JP5164849B2 (ja) 2013-03-21
TW200738250A (en) 2007-10-16
AR057922A1 (es) 2007-12-26
CA2630833A1 (en) 2007-05-31
CA2630833C (en) 2015-01-06
US7897159B2 (en) 2011-03-01
EP1951274A1 (en) 2008-08-06
CN101312737B (zh) 2012-11-14
PT1951274E (pt) 2009-12-14
ATE450266T1 (de) 2009-12-15
US20090035269A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
HUS1700015I1 (hu) PDGFR-alfa elleni antitest és alkalmazása tumorok kezelésénél
IL186662A0 (en) Combination cancer therapy with
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
HK1201182A1 (en) Pegylated il-10 for use in treating cancer or tumor il-10
IL201211A (en) K3 ip-alpha quinoxaline inhibitors for use in combination with chemotherapeutic agents for use in the treatment of cancer
EP1940456A4 (en) WWOX GENE, VECTORS COMPRISING THE SAME, AND USES THEREOF IN THE TREATMENT OF CANCER
PL2358697T3 (pl) Związki izoindolinowe do zastosowania w leczeniu raka
HK1215683A1 (zh) 抗葉酸藥在癌症治療中的聯合應用
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
PL2564872T3 (pl) Mazindol sam lub w kombinacji z żelazem do leczenia deficytu uwagi/nadpobudliwości
HK1117427A1 (en) Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
EP1891047A4 (en) A 1-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID SUITABLE FOR THE CHEMOTHERAPY OF CANCER
EP1952811A4 (en) USE OF ERIOCALYXIN B FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF LEUKEMIA
GB0517387D0 (en) Combinations for the treatment of cancer
HK1151971A1 (en) Compounds for use in the treatment of cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
AU307436S (en) Angle grinder
AU303295S (en) Belt
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
IL190334A0 (en) Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents
IL185518A0 (en) 1,3-thiazole-5-carboxamides useful as cancer chemotherapeutic agents

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20141012